Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
Emory University
NovoCure Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
University of Nebraska
National Cancer Institute (NCI)
University of Kentucky
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeiGene
Mural Oncology, Inc
BeiGene
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Trishula Therapeutics, Inc.
University of Colorado, Denver
Ohio State University Comprehensive Cancer Center
Mayo Clinic
City of Hope Medical Center
M.D. Anderson Cancer Center
NRG Oncology
Thomas Jefferson University
University of Chicago
Thomas Jefferson University
M.D. Anderson Cancer Center
City of Hope Medical Center
Columbia University
Mayo Clinic